Announcement PDF RNS Number : 7870V N4 Pharma PLC 10 April 2019 10 April 2019 N4 Pharma Plc ("N4 Pharma" or the "Company") Director/PDMR shareholding N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces that Nigel Theobald, Chief Executive Officer of the Company, has purchased 67,343 ordinary shares in the Company ("Ordinary Shares") at a price of 4.44 pence per Ordinary Share. In addition, Anne-Marie Lawrence, wife of Nigel Theobald and a person closely associated with him, has today purchased 67,343 Ordinary Shares at a price of 4.44 pence per Ordinary Share. As a result of these purchases, Nigel Theobald's interest in the Company is now 16,981,319 Ordinary Shares, which represents approximately 16.74 per cent. of Company's issued share capital. Enquiries: N4 Pharma Plc Nigel Theobald, CEO Via Alma PR Allenby Capital Limited James Reeve/Asha Chotai Tel: +44(0)203 328 5656 Scott PR Georgia Smith Tel: +44(0)1477 539 539 About N4 Pharma plc N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 2 Reason for the notification a) Position/status b) Initial Initial notification notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 3 Nigel Theobald Chief Executive Officer a) Name N4 Pharma PLC b) LEI 213800I841D2RKMFK955 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of Ordinary shares of 0.4p the financial instrument, type of GB00BYW8QM32 instrument Identification code Nature of the Purchase of ordinary shares in the Company transaction a) b) c) d) Price(s) and volume(s) Aggregated Price(s) Volume(s) 4.44p 67,343 Aggregated volume: 67,343 information - Aggregated volume - Price Weighted average price: 4.44 pence per share e) Date of the transaction 10 April 2019 f) Place of the transaction London Stock Exchange, XLON 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 2 Reason for the notification a) Position/status b) Initial Initial notification notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 3 Anne-Marie Lawrence Wife and PCA of Chief Executive Officer a) Name N4 Pharma PLC b) LEI 213800I841D2RKMFK955 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of Ordinary shares of 0.4p the financial instrument, type of GB00BYW8QM32 instrument Identification code Nature of the Purchase of ordinary shares in the Company transaction a) b) c) Price(s) and volume(s) Price(s) Volume(s) 4.44 67,343 d) Aggregated information - Aggregated volume - Price Aggregated volume: 67,343 Weighted average price: 4.44 pence per share e) Date of the transaction 10 April 2019 f) Place of the transaction London Stock Exchange, XLON This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END DSHEAELEFSENEFF